中国科学院大学附属肿瘤医院（浙江省肿瘤医院）王晓稼课题组博士后招聘启事中国科学院大学附属肿瘤医院（浙江省肿瘤医院）乳腺肿瘤内科王晓稼主任在研项目汇总历史回顾丨新一代多基因模型预测亚裔早期激素敏感型乳腺癌患者术后10年远处转移风险的验证性研究（2019SABCS）历史回顾丨亚裔多基因预测复发风险模型（2019ASCO）参与的国内国际临床试验 Lancet Oncol Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial Xiaojia Wang (2015) Oncotarget Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China Xiaojia Wang (2016) Oncotarget Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study Xiaojia Wang (2016) Breast Cancer Res Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1 Xiaojia Wang (2017) Lancet Oncol Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial Xiaojia Wang (2017) Eur J Cancer Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial Xiaojia Wang (2019) Lancet Oncol Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial Xiaojia Wang (2019) Invest New Drugs Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial Xiaojia Wang (2020) Breast Cancer Res Treat Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study Xiaojia Wang (2020) Adv Med Oncol MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study Xiaojia Wang (2020) Lancet Oncol Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Xiaojia Wang (2021) |
|
|
